The involvement of interleukin-1 (IL-1) in inflammation, tumor growth, and metastasis makes it an attractive target for therapeutic intervention. Here, we show that a continuous delivery of a low, but steady-state level of the naturally occurring IL-1 receptor antagonist (IL-1Ra) reduced inflammatory responses and inhibited tumor development in mice, phenomena that are induced by IL-1, mainly secretable IL-1β. The IL-1Ra was delivered from microencapsulated genetically engineered cells, which overexpress and secrete this mediator. For a tumor model, we used fibrosarcoma cell line, which secretes high levels of IL-1β; when injected s.c. into mice, the cells developed into large tumors characterized by very active angiogenic patterns. The proangiogenic features of IL-1β were manifested at low levels of the cytokine, and release of 25 ng per day of the IL-1Ra was needed to oppose its effects and inhibit tumor development. The continuous delivery of the IL-1Ra contributed to improved biocompatibility of the microencapsulated cell systems; the fibrotic sac surrounding the systems was much thinner with significantly less blood capillaries and inflammatory cells. Not only do our findings point to the antiangiogenic properties of IL1Ra in inflammation and tumor growth, but they also provide a more efficient and convenient way for treating diseases involving IL-1.
nterleukin-1β (IL-1β) is a multifunctional cytokine that is involved in inflammatory and immunological processes but also contributes to tumor growth and metastasis (1, 2) . Its ability in these processes stems mainly from inducing other cytokines, chemokines, and pro-inflammatory molecules. In several models of cancer, such as in melanoma, IL-1β increases tumor growth and metastasis (3) (4) (5) . Aside from this, there are reports that IL-1 is involved in tumor angiogenesis, either by itself or via the induction of angiogenic factors, such as basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in endothelial cells as well as tumor stromal cells (6) .
I
Angiogenesis plays a paramount role not only in tumor growth and metastasis but also in the progression of inflammation. The possibility that IL-1β is an upstream modulator of angiogenesis may provide an avenue to control these processes using IL-1 inhibitors. One such inhibitor is the naturally occurring IL-1 receptor antagonist (IL-1Ra), which binds to IL-1 receptors without transmitting an activation signal. IL-1Ra reduced murine B16 melanoma metastases in the liver (3, 4) . IL-1Ra is safe when injected into humans (7) , and it is approved for treating the signs and symptoms of rheumatoid arthritis (RA) (8) . Because of its short half-life of ~6 h, daily s.c. injections of IL-1Ra are used in patients with RA.
To provide for a sustained, steady-state delivery of IL-1Ra in potential future therapeutic treatment protocols, we genetically engineered NIH/3T3 cells to continuously secrete IL1Ra. The cells were encapsulated within alginate-poly(L-lysine)-alginate (APA) microspheres, which provide an immunoisolation barrier for the entrapped cells (9) . In addition, the APA microspheres are permeable to allow free diffusion of nutrients to the cells, which maintain their viability, and the exit of IL-1Ra once it is secreted from the cells (10) . Once implanted in the vicinity of tumors, these microspheres should function as a micro-bioreactor to deliver a continuous source of IL-1 inhibitor. Such treatment protocol should circumvent the problems of the short half-life of IL-1Ra and the need for repetitive administrations of bolus cytokine injection.
To investigate the feasibility of our approach, a fibrosarcoma tumor that constitutively expresses and secretes IL-1β was chosen as a model for a malignant tumor. At first, the angiogenic profile of tumors of IL-1β-transfected cells was characterized. We then examined the ability of a continuous delivery of IL-1Ra to inhibit angiogenesis and tumor growth in mice.
MATERIALS AND METHODS

IL-1Ra cell transfection
IL-1Ra secreting cells were produced by transfecting NIH/3T3 cell line with pLXSN retroviral vector bearing the IL-1Ra encoding region (a gift from Dr. John Morris, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC). The infectious particles, following a passage in the PA317 packaging line, had an amphotropic helper virus and the Neo gene, which confers resistance to the aminoglycoside G418. The infected cell clones were selected with G418 (200 µg/ml) and screened for IL-1Ra secretion with an enzymelinked immunosorbent assay (ELISA), using polyclonal antibodies specific to IL-1Ra (11) . The highest secreting clone was isolated and further propagated in culture (Dulbecco's modified Eagle's medium [DMEM] , with 10% [v/v] fetal calf serum [FCS] , 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine [Biological Industries, Israel]).
Cell encapsulation
The cells were encapsulated within calcium alginate hydrogel microspheres, which were then reacted with poly(L-lysine) (PLL) to form a complex polyelectrolyte membrane, with permeability properties depending on the molecular weight of PLL (11, 12) . In brief, the cells were suspended in 2% (w/v) sterile sodium alginate (Protanal SF 120, >65% guluronic acid, Pronova Biopolymers, Drammen, Norway), to a final concentration of 3 × 10 6 cells/ml and 1% (w/v) alginate. Spherical hydrogel droplets were formed by extrusion of the cellalginate suspension, through a droplet-forming apparatus, into 200 ml of the ionic crosslinker solution (1.5% [w/v] calcium chloride). The microbeads were further reacted with 0.05% (w/v) PLL solution (PLL-HBr, 87 kDa, Sigma Chemical Co., St. Louis, MO) for 6 min and thrice washed with saline. The second coating was achieved by suspending the beads in 0.125% (w/v) alginate solution for 4 min and washing with saline. The cell-loaded microspheres were incubated in DMEM as above, under standard tissue conditions. The viability of the microencapsulated cells was determined by the MTT viability assay (13) .
To follow the encapsulated cells, we labeled them before encapsulation with the fluorescence marker DiOC18 (Molecular Probes, Eugene, OR), which stains the cell membrane in green. The dye (0.008 mg/ml DMSO) was added to the plate at a volume ratio of 1 µl/ml medium.
Tumor model and vascular density
Clone 3-ssIL-1β tumor cells were derived from NIH/3T3 cells, transformed by transfecting them with the TPR-met oncogene (14) , and later transfected with the pLXSN retroviral vector bearing the IL-1β encoding region fused to signal peptide (15) . In the ssIL-1β transfected fibrosarcoma cells, IL-1β is mainly secreted with traces of the cytokine in the cytosol. As a control, we used Clone 3-LXSN tumor cells, which were transfected with the empty vector. Tumors were established in syngeneic NFS/N mice following s.c. injection of 7.5 × 10 4 tumor cells (either Clone 3-ssIL-1β or Clone 3-LXSN) into the right flank. Tumor diameter was measured with a caliper thrice weekly. When the tumor size reached 0.3, 1.5, or 3 cm in diameter, the mice were killed and the tumors were dissected, fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned into 4-µm slices. After deparaffinization of the samples, the slides were reacted with rabbit anti-human von Willebrand factor (vWF, DAKO, Glostrup, Denmark) diluted 1:200 in BSA/PBS for 2 h. Staining was visualized using the Envision +System kit (DAKO). Quantification of capillary number was performed by a procedure described by Weidner et al. (16) , wherein at least three areas of the highest vascularity are screened, using low magnification (×40). The number of capillaries in these areas was determined at ×200 magnification, using ImagePro 3 software.
Microsphere injection into normal and tumor cell-injected mice
The study was performed according to the guidelines of the Institutional Animal Care and Use Committee. Healthy, 8-wk-old NFS/N mice received an s.c. injection of 0.5 ml APA microspheres encapsulating 3T3/IL-1Ra or NIH/3T3 (wild-type) cells. At different times later, the mice were killed and the microspheres and surrounding tissues were recovered. To determine cell viability by MTT assay and IL-1Ra secretion by ELISA, we washed the retrieved microspheres with phosphate-buffered saline (PBS) and cultured them under standard conditions. Vascularity of the tissue surrounding the microspheres (i.e., the fibrotic sac) was determined on hematoxylin and eosin (H&E)-stained thin sections (4 µm thickness). The number of capillaries in 15 different fields, randomly selected from captured images of three H&E-stained slides from each animal was determined using ImagePro 3. The results of capillary density are reported as mean ± SD. Statistical analysis of data was performed by analysis of variance (ANOVA) single factor, using Excel Software 2000.
In the tumor inhibition studies, NFS/N tumor (Clone 3-ssIL-β)-bearing mice received two s.c. injections of IL-1Ra secreting microspheres near the tumor site, on days 6 and 11 after tumor cell injection. Each injection consisted of 0.5 ml APA microspheres releasing a total of 25 ng IL-1Ra per day. Control tumor-bearing mice were injected with microspheres containing the NIH/3T3 (wild-type) cells or were not treated after tumor cell inoculation. Tumor development in the different mice was followed thrice weekly using a caliper.
RESULTS
Microencapsulated cells secreting hIL-1Ra
NIH/3T3 cells were transfected with the pLXSN retroviral vector bearing the human IL-1Ra encoding region. Stable clones (n=14) were screened by an ELISA specific for human IL1Ra. The clone (3T3/IL-1Ra) secreting the highest level of the cytokine (20 ng/10 6 cells/day) was chosen for encapsulation. In contrast, no IL-1Ra was detected in the media from the parental (NIH/3T3) or mock-transfected (3T3-pLXSN) cell lines.
The 3T3/IL-1Ra cells were encapsulated within 450-µm-diameter APA microspheres, at an initial cell density of 3 × 10 6 cells/ml microspheres (Fig. 1A) . The microsphere size and permeability of the alginate-polylysine (87 kDa) membrane were optimized for maintaining cell viability and for allowing IL-1Ra release from the microspheres (11) . Viable encapsulated cells were detected for at least 2 wk in culture, and the microspheres released IL-1Ra at a rate of 19-25 ng/ml microspheres/day (Table 1, in vitro).
To test whether the in vitro IL-1Ra secretion profile is manifested in vivo, microspheres containing the IL-1Ra secreting cells were s.c. injected into syngeneic NFS/N mice, and at various intervals thereafter, the microspheres were retrieved and assayed for cell viability and IL-1Ra secretion (Table 1, in vivo). Figure 1B is a picture of 3T3/IL-1Ra-loaded microspheres retrieved 7 days postimplantation. The microspheres appear to be intact, and they are coated with a thin white fibrotic layer. MTT viability assay revealed that within the first 2 wk, the in vivo viability of the encapsulated cells was maintained close to the preimplantation level (Table 1) . This accounted for the high level of IL-1Ra secretion during this time period, 24-28 ng/ml microspheres/day.
Inhibition of tumor growth
With a system continuously secreting IL-1Ra, we examined the capability of this delivery system to inhibit the development of a tumor from ssIL-1β-transfected fibrosarcoma cells (Clone 3-ssIL-1β). This tumor cell line was transfected with a fused gene containing the mature form of IL-1β linked to a signal peptide, to enable efficient secretion of the cytokine through the ER-Golgi pathway (15) . In culture, the tumor cell line secreted IL-1β at a rate of 1 ng/1 × 10 6 cells/day and after injecting 1 million cells into NFS mice, the serum level of IL-1β on day 10 is 2 ng/ml (Apte, unpublished results). Expression and secretion of IL-1β increased the invasiveness and metastatic capacity of the malignant cells compared with nontransfected cells and also increased the angiogenic response in the tumors (21) .
At first, we examined the angiogenic patterns in tumors derived from s.c. injected Clone 3-ssIL-1β cells compared with those of cells of the mock-transfected cells of Clone 3-LXSN. NFS/N mice were injected with a minimal tumor dose of 7.5 × 10 4 cells, as experimentally determined (data not shown). Palpable tumors were developed within 5 days after tumor cell injection s.c. On day 6, the tumors had diameters of 0.3 cm, and within 40 days, they reached a diameter of 3 cm. Histology revealed that the IL-1β-expressing tumors were hypervascularized compared with the tumors derived from the mock-transfected cells (Fig. 2 and Table 2 ). Differences between the tumors were already observed 7 days after tumor cell injection (Fig. 3A) . The tumors derived from IL-1β-expressing cells were characterized by high mitotic activity and an infiltration of greater numbers of inflammatory cells, mainly neutrophils but also some lymphocytes and macrophages, compared with the tumors derived from the mock-transfected cells. In the ssIL-1β tumors, the mononuclear infiltrate is mainly localized in the outskirts of the tumors, whereas neutrophils invaded necrotic areas throughout the tumor.
With the progression of tumor development, blood vessels in the IL-1β-expressing tumors were irregular and larger in size (Fig. 2B ) compared with tumors derived from the mocktransfected cells of a similar gross size (Fig. 2C) . Although the number of blood vessels was similar for the two tumors, at the different time points of tumor development, the percentage area occupied by the blood vessels in the tumor sections from IL-1β-expressing tumors was two to three times larger that that observed in those derived from Clone 3-LXSN cells (Table 2) . In both tumors, a decrease in capillary density with time was noted, probably due to fusion of capillaries to generate larger blood vessels.
The inhibitory effect of the continuously delivered IL-1Ra on the angiogenic IL-1β-transfected fibrosarcoma tumor was examined. During the course of tumor development from Clone 3-ssIL-1β cells, mice were treated with two injections of IL-1Ra-secreting microspheres at tumor vicinity, on days 6 and 11 after tumor cell injection. Each injected dose of microspheres secreted 25 ng of IL-1Ra per day near the tumor cell site. Controls consisted of tumor-bearing mice treated with microencapsulated wild-type NIH/3T3 cells, or without treatment. The continuous delivery of IL-1Ra from the microencapsulated cells resulted in complete tumor eradication in 82% of the tumor-bearing mice ( Fig. 3 and Table  3 ). In the 18% of remaining mice, tumor growth rate was significantly inhibited as compared with the other groups (Fig. 3A) . The survival rates (Fig. 3B) reveal that 45 days after tumor cell injection, all tumor-bearing mice in the control groups had died. In contrast, at this time point, all mice treated with microencapsulated IL-1Ra-secreting cells were alive. Microencapsulated wild-type NIH/3T3 or mock-transfected NIH/3T3 (NIH/3T3-LXSN) did not have any effect on tumorigenicity patterns.
Biocompatibility of IL-1Ra-secreting microspheres
The biocompatibility of the IL-1Ra-secreting microspheres was further evaluated in normal NFS/N mice. Microspheres encapsulating either the IL-1Ra-secreting cells or the wild-type NIH/3T3 cells were injected s.c. into two groups of mice (n=5 each). Thirty days later, the microsphere injection site was dissected, grossly examined, and evaluated histologically. Macroscopic examination revealed a hypervascularized fibrotic sac surrounding the NIH/3T3 cells-loaded microspheres, whereas much less vascularized tissue surrounded the microspheres that contained the IL-1Ra-secreting cells (Fig. 4A) . Empty APA microspheres did not elicit such a fibrotic sac formation (data not shown).
Histology of thin sections from the retrieved fibrotic capsule of the 3T3/NIH-loaded microspheres revealed infiltration of inflammatory cells, such as granulocytes, lymphocytes, macrophages, and fibroblasts embedded in collagen fibers. The tissue was enriched with capillaries of different sizes (Fig. 4B) . A different picture was seen with the implanted IL1Ra-secreting microspheres. The fibrotic sac surrounding the microspheres was noticeably thinner than that surrounding the 3T3/NIH microspheres, and the capillaries were smaller in number and size. Quantification of capillary density in the fibrotic tissue surrounding the IL1Ra-secreting microspheres revealed twofold less capillaries than that counted in the tissue surrounding 3T3/NIH microspheres (Fig. 4C, significance P=0.01) .
DISCUSSION
In the present work, we demonstrate that the continuous delivery of IL-1Ra from microencapsulated engineered cells inhibited tumor development in mice injected with fibrosarcoma cells that constitutively express and secrete IL-1β (Clone 3-ssIL-1β) and that have served as a model for assessing the effects of tumor cell-associated IL-1β on malignant patterns. In contrast, control mice injected with tumor cells overexpressing IL-1β, but either not treated or treated with microspheres encapsulating the wild-type 3T3/NIH cells, developed hypervascularized violent tumors.
IL-1Ra is the naturally occurring inhibitor of pre-formed IL-1. In fact, in mice deficient in IL-1Ra, two severe inflammatory diseases spontaneously develop, an RA-like multiple joint disease (17) and a lethal large vessel arteritis (18) . Thus, in the absence of IL-1Ra, IL-1 activities are unopposed and disease develops. In our tumor model, the continuous local secretion of IL-1β has led to the development of hypervascularized invasive tumors with large and branched blood vessels, much more than those observed in the wild-type tumors, indicating that IL-1 incuses in vivo pronounced angiogenesis. Recently, two additional studies pointed to the direct effect of host-derived IL-1 on tumor angiogenesis. Saijo et al. (19) reported that tumors derived from IL-1β-transfected Lewis lung carcinoma cells grew faster compared with control and showed more abundant vasculature. Apte's group (20) demonstrated the role of IL-1β as an in vivo regulator of tumor angiogenesis, using IL-1β knockout mice and transplantable tumors as well as fibrosarcoma cells overexpressing IL-1β, including the cells transfected with the ssIL-1β construct that was used in the present study (21) .
The proangiogenic effects of IL-1β may include direct effects of IL-1 on endothelial cell proliferation and secretory function or may be mediated via a cascade of IL-1-induced angiogenic factors, such as bFGF and VEGF, that are secreted from the malignant or stromal cells through autocrine and paracrine pathways. Indeed, elevated levels of VEGF were detected in the conditioned medium of cultured fibrosarcoma cells transfected with the ssIL-1β constructs compared with the wild-type or mock-transfected fibrosarcoma cells (Apte, unpublished results ).
An additional support to the direct involvement of IL-1 in angiogenesis is our finding that the continuous delivery of its inhibitor, the IL-1Ra, significantly reduced the number of blood capillaries in the fibrotic sac that surrounded the microencapsulated cell systems. In this case, IL-1 of host (microenvironmental) origin possibly induces this process. The decline in the capillary density was associated with a significant reduction in the inflammatory response, thus leading to a much thinner fibrotic sac. The formation of a thick angiogenic fibrotic sac around the microencapsulated wild-type 3T3/NIH cells is attributed possibly to cell secretions that diffused out of the microspheres and induced host inflammatory responses. The APA microspheres themselves have not shown such responses in the present or previous studies (12) . In future studies, the selection of cell line for genetic manipulation should take into consideration the possible effects of cell secretions on the development of an inflammatory response in the host. Nevertheless, our studies reveal that the continuous delivery of IL-1Ra can control and reduce inflammatory responses, for example, by inhibiting angiogenesis.
Of considerable importance was the observation that the near total prevention of this aggressive angiogenic response to the IL-1β-secreting tumors was accomplished by microspheres locally secreting low but steady-state levels of IL-1Ra (25 ng/day). In contrast, inhibition of hepatic B16 melanoma metastasis required 10 repeated bolus injections of 10 mg/kg (4). One can conclude that the proangiogenic and protumorigenic properties of IL-1β are taking place at relatively low levels of the host-or tumor cell-derived cytokine. Indeed, Apte et al. (unpublished results) showed that Clone 3-ssIL-1β cells secrete IL-1β at a rate of 1 ng/1 × 10 6 cells/day, in culture, and after injecting 1 million cells into NFS/N mice, the serum level of IL-1β on day 10 is 2 ng/ml. Yet, these malignant cells developed into highly angiogenic tumors when s.c. injected into mice, much more than the mock-transfected cells. Furthermore, ssIL-1β-secreting cells induced experimental lung metastases upon i.v. injection, whereas parental cells or mock-transfected cells are inert in that aspect.
Another important conclusion drawn from our results is that local steady-state secretion of IL-1Ra is more effective than the peak-and-valley values obtained after bolus injections of the cytokine. In rats with collagen-induced arthritis, the administration of IL-1Ra by osmotic pump at 5 mg/kg/h reduced disease severity by 90% in joints distal to the pump (22) . In our tumor model, two injections of IL-1Ra-secreting microspheres, administered on days 6 and 11 after tumor cell inoculation, were able to prevent tumor growth in 82% of the mice, and in the remaining 18%, a significant delay in tumor growth was achieved. The two microsphere injections provided an effective therapeutic level of the IL-1 inhibitor that was able to neutralize the activity of IL-1β and the cascade of the downstream angiogenic factors induced by it. Thus, neutralizing of a signal upstream pro-inflammatory cytokine, that is, IL-1β, may be sufficient to prevent or attenuate the cascade of angiogenic factors. We hypothesize that this is advantageous as compared with neutralizing of single factors, because angiogenesis is mediated by multiple pro-angiogenic factors with overlapping and redundant functions that are all induced by a single stimuli, for example, IL-1.
These results point to the possibility of using the IL-1Ra in anticancer therapies, in addition to its effective use in chronic inflammatory diseases, such as RA, as many tumors have been shown to produce and secrete IL-1 or to induce its production by stromal cells in the vicinity of the tumor. Thus, the use of IL-1Ra in cancer therapy may reduce tumor growth and also alleviate side-effects that are induced by tumor-associated inflammatory responses, such as cachexia and tissue damage. Our strategy directed at the blockade of IL-1 activity alone or as an adjunct to the existing therapies may therefore be beneficial in the treatment of tumors using FDA (Food and Drug Administration)-approved IL-1Ra and poly(lactic-co-glycolic acid) (PLGA) microspheres. We believe that the use of a delivery system would help in adapting this treatment to clinical situations and in enhancing patient compliance. Retrieved from the subcutis site, 7 days postinjection into mice. The cells were stained with DiOC18, which stains the cell membrane in green. Magnification: ×60 (A), ×40 (B). The number of mice in the different groups is specified in Table 3 . 
